Vicente Anna Luiza Silva Almeida, de Souza Santos Fabiana Aparecida, Hirai Welinton Yoshio, Lissa Delphine, de Oliveira Cavagna Rodrigo, da Silva Aline Larissa Virginio, Dos Reis Mariana Bisarro, da Silva Eduardo Caetano Albino, da Silva Flávio Augusto Ferreira, Mourão Josiane Dias, De Marchi Pedro, de Carvalho Ana Carolina, Leal Letícia Ferro, Reis Rui Manuel
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
Department of Epidemiology and Biostatistics, Barretos Cancer Hospital, Barretos, Brazil.
Clin Epigenetics. 2025 Feb 17;17(1):25. doi: 10.1186/s13148-025-01831-1.
Homeobox A9 promoter methylation (HOXA9) has been reported as a biomarker for early lung adenocarcinoma patients' prognosis. We aim to evaluate its prognostic value, regardless of disease stage. Using droplet digital PCR, we measured HOXA9 methylation in a cohort comprising 161 Brazilian patients. Low HOXA9 methylation was associated with higher cancer-specific survival but showed no significance after adjustment for clinical covariates. While low HOXA9 methylation was associated with earlier stages, no survival association was observed in this subset of patients. Overall, HOXA9 promoter methylation is not an independent prognostic biomarker of cancer-specific survival in Brazilian lung adenocarcinomas patients.
同源盒A9启动子甲基化（HOXA9）已被报道为早期肺腺癌患者预后的生物标志物。我们旨在评估其预后价值，而不考虑疾病分期。使用液滴数字PCR，我们在一个包含161名巴西患者的队列中测量了HOXA9甲基化。低HOXA9甲基化与较高的癌症特异性生存率相关，但在调整临床协变量后无显著性差异。虽然低HOXA9甲基化与早期阶段相关，但在这一亚组患者中未观察到生存相关性。总体而言，HOXA9启动子甲基化不是巴西肺腺癌患者癌症特异性生存的独立预后生物标志物。
